Apollo Hospitals Stock: Citi Sets ₹9,600 Target Amid Strong Earnings

Introduction

Apollo Hospitals Enterprise Ltd. has been a focal point for investors, with its stock performance reflecting a blend of robust financial growth and operational challenges. The company recently posted strong quarterly earnings, yet its stock has underperformed some peers. This has led to divergent views from brokerage firms, with Citi raising its price target to a street-high of ₹9,600, citing an attractive valuation, while others like ICICI Securities have adopted a more cautious stance. This analysis examines the company's recent performance, the factors driving analyst ratings, and the outlook for its various business segments.

Stellar Financial Performance in FY26

Apollo Hospitals has demonstrated consistent financial strength through the first half of fiscal year 2026. In the first quarter ending June 2025, the company reported a significant 41.80% year-on-year surge in consolidated net profit, which reached ₹432.80 crore. This growth was supported by a 14.87% increase in revenue from operations, totaling ₹5,842.10 crore. The momentum continued into the second quarter ending September 2025, with net profit rising 25.98% to ₹477.20 crore on sales of ₹6,303.50 crore. Key profitability metrics also showed improvement, with EBITDA for Q1 FY26 growing by 26.22% to ₹852 crore.

Citi's Bullish Outlook and Raised Target

Global brokerage firm Citi has reaffirmed its 'high-conviction buy' rating on Apollo Hospitals, increasing its target price to ₹9,600. This suggests a potential upside of over 35% from recent trading levels. Citi's confidence stems from the belief that the stock's recent correction has made its valuation attractive. The brokerage argues that near-term headwinds, such as temporary disruption in patient inflows from Bangladesh and initial losses from new hospitals, have already been factored into the current share price. Looking ahead, Citi projects a strong consolidated EBITDA compound annual growth rate (CAGR) of 23% between FY25 and FY28, driven by the scaling up of new facilities and growth in its HealthCo segment.

Near-Term Headwinds and Operational Metrics

Despite the positive financial results, Apollo Hospitals is navigating some operational challenges. The company is expected to incur losses of around ₹200 crore over FY26-27 from its newly commissioned hospitals. These initial costs are anticipated to keep hospital EBITDA margins relatively flat at approximately 24% in the near term. However, analysts expect margin expansion of over 100 basis points by FY28 as these new facilities achieve higher occupancy and operational efficiency. Additionally, overall hospital occupancy was reported at 65% in Q1 FY26, a slight decrease from 68% in the same period last year, partly influenced by a reduction in international patient flow.

A Contrasting View: ICICI Securities' Downgrade

Presenting a more conservative perspective, ICICI Securities downgraded Apollo Hospitals' stock to 'HOLD' from 'Add', with a revised target price of ₹8,080. The brokerage's decision was influenced by what it described as slower growth in the hospital business, which grew around 9% year-on-year in Q2 FY26. Citing the impact of a high base and lower international patient numbers, ICICI Securities trimmed its EBITDA estimates for FY26 and FY27 by approximately 1%. This cautious stance highlights the market's sensitivity to growth moderation in the core hospital segment.

Long-Term Growth Drivers

The long-term outlook for Apollo Hospitals remains robust, supported by strategic expansion and diversification. The company is on track to add approximately 1,257 beds over the next 18 months, primarily in metro cities where it commands higher average revenue per occupied bed (ARPP). Furthermore, the Apollo HealthCo segment, which includes the Apollo 24x7 digital platform and offline pharmacies, is transitioning from a cost center to a value creator. With the planned merger of Keimed and a projected revenue run rate of ₹25,000 crore by FY27 for the combined health-tech entity, this division is set to become a significant contributor to overall growth.

Analyst Consensus and Price Targets

Overall analyst sentiment remains largely positive. Out of 26 analysts covering the stock, a significant majority maintain a 'Buy' recommendation. Wall Street analysts have set an average 1-year price target of ₹8,911.03. The forecasts vary, reflecting different assumptions about the company's ability to navigate short-term challenges and capitalize on long-term opportunities.

Conclusion

Apollo Hospitals Enterprise presents a compelling case of a market leader with strong financial performance facing manageable near-term operational hurdles. While the company's expansion will temporarily weigh on margins, its long-term strategy of increasing bed capacity, scaling its pharmacy and digital health businesses, and improving case mix provides a clear path for sustained growth. Investors are currently weighing the bullish long-term outlook articulated by firms like Citi against the more cautious short-term view from others. The company's ability to efficiently ramp up its new hospitals and grow its HealthCo segment will be critical in determining its stock performance moving forward.